Chemical Characterization of Rosmarinus officinalis L.Hydrodistillation By-Products, Evaluating Their Antioxidant, and Anticancer Activities.

Document Type : Original Article

Authors

1 Associate professor of Agricultural biochemistry Faculty of Agriculture, Zagazig University

2 BSc of Agricultural biochemistry Faculty of Agriculture, Zagazig University

3 Professor of Agricultural biochemistry Faculty of Agriculture, Zigzag University

4 Professor of Agricultural Biochemistry Faculty of Agriculture, Zag zig University

5 Associate professor of Agricultural biochemistry Faculty of Agriculture, Zag zig University

Abstract

Essential oils derived from Mediterranean plants are widely used; nevertheless, the hydrodistillation waste produced with these oils are relatively unexplored and underutilized. With only partial data available in the literature, we analysed the chemical composition of by-products from hydrodistilled rosemary leaves. The solid residue of rosemary by-product (RSB) was extracted using 80% ethanol. The extract was tested for antioxidant activity and demonstrated a high effect. The overall phenolic content was 188 mg GAE/g, whereas the flavonoid content was 12 mg QE/g. caffeic acid (31.2%), naringenin (27.8%), apigenin (7.39%), hesperetin (5.06%), and coumaric acid (3.94%) were the most common components of RSB. the inhibitory concentration that inhibits 50% of the cancer cell population (IC50) for the cytotoxic action of RSB extract against HCT 116 (human colon) and PC3 (human prostate) cancer cell lines at varied concentrations (31.25-1000 µg/mL) was 31.4 µg/mL for HCT 116 and 33.4 µg/mL for PC3.We conclude that the solid residue of rosemary by-product leaves exhibits significant potential in the development of phyto-medicines with anticancer properties. Drugs derived from rosemary solid by-product (RSB) could serve as an alternative medicinal source due to their anticancer activity. Furthermore, this study suggests that the ethanol extract of this by-product possesses the greatest potential for anticancer activity against (HCT 116) Human colon and human Prostate (PC3) cancer cell lines.

Introduction

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 17 August 2024
  • Receive Date: 04 July 2024
  • Revise Date: 09 August 2024
  • Accept Date: 17 August 2024